- Home
- BBNX vs SLP Comparison
BBNX vs SLP Comparison
Compare BBNX & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBNX
- SLP
- Stock Information
- Founded
- BBNX 2015
- SLP 1996
- Country
- BBNX United States
- SLP United States
- Employees
- BBNX N/A
- SLP N/A
- Industry
- BBNX Medical/Dental Instruments
- SLP EDP Services
- Sector
- BBNX Health Care
- SLP Technology
- Exchange
- BBNX Nasdaq
- SLP Nasdaq
- Market Cap
- BBNX 841.5M
- SLP 675.9M
- IPO Year
- BBNX 2025
- SLP 1997
- Fundamental
- Price
- BBNX $17.89
- SLP $17.16
- Analyst Decision
- BBNX Strong Buy
- SLP Buy
- Analyst Count
- BBNX 10
- SLP 7
- Target Price
- BBNX $25.20
- SLP $40.40
- AVG Volume (30 Days)
- BBNX 504.1K
- SLP 454.9K
- Earning Date
- BBNX 08-06-2025
- SLP 07-02-2025
- Dividend Yield
- BBNX N/A
- SLP 0.35%
- EPS Growth
- BBNX N/A
- SLP N/A
- EPS
- BBNX N/A
- SLP 0.36
- Revenue
- BBNX $69,830,000.00
- SLP $78,564,000.00
- Revenue This Year
- BBNX $32.79
- SLP $27.66
- Revenue Next Year
- BBNX $36.59
- SLP $6.75
- P/E Ratio
- BBNX N/A
- SLP $47.57
- Revenue Growth
- BBNX 38911.17
- SLP 21.49
- 52 Week Low
- BBNX $8.89
- SLP $17.05
- 52 Week High
- BBNX $24.50
- SLP $49.72
- Technical
- Relative Strength Index (RSI)
- BBNX N/A
- SLP 18.67
- Support Level
- BBNX N/A
- SLP $18.66
- Resistance Level
- BBNX N/A
- SLP $28.65
- Average True Range (ATR)
- BBNX 0.00
- SLP 1.74
- MACD
- BBNX 0.00
- SLP -1.05
- Stochastic Oscillator
- BBNX 0.00
- SLP 3.78
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product includes the iLet Bionic Pancreas (iLet). The Company operates as a single segment, focused on the development, manufacture and sale of the iLet.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It includes two segments. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.